The Antiemetic Effects of Increased Splanchnic Perfusion, Induced by the Gut Hormone GIP, in Healthy Individuals

Status

Enrolling by invitation

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07687589

Acronym

GIP EMESIS

Enrollment

Registered

2026-07-07

Start date

2026-05-19

Completion date

2027-04-28

Last updated

2026-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Emesis

Keywords

GIP, emesis, GLP-1, incretin hormones, nausea

Brief summary

This study investigates whether the gut hormone glucose-dependent insulinotropic polypeptide (GIP) can reduce feelings of nausea. GIP is naturally released after meals and is administered intravenously to healthy participants during the experiment. Nausea is induced using either glucagon-like peptide 1 (GLP-1), another gut hormone, or apomorphine, a medication known to trigger nausea. By combining these substances, the study aims to determine whether GIP can alleviate nausea. The findings may improve understanding of interactions between the gut and the brain.

Interventions

OTHERGlucose-dependent Insulinotropic Polypeptide (GIP)

GIP - gut hormone

OTHERGLP-1 (7-36) amide

gut hormone - GLP-1(7-36)NH2

OTHERApomorphine Injectable Solution

used as a tool to induce nausea

OTHERSaline (0.9% NaCl)

Placebo

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

SUPPORTIVE_CARE

Masking

DOUBLE (Subject, Investigator)

Intervention model description

Double-blinded, randomized, placebo-controlled, crossover study

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Men or women, age of 18-60 years * BMI between 19-27 kg/m2 (both included) * informed consent

Exclusion criteria

* Current or past treatment with GLP-1 or GIP/GLP-1 receptor-targeting compounds within the last six months * Gastrointestinal disorders that the investigator evaluates could interfere with induction of nausea (e.g. gastroparesis, functional dyspepsia and GI surgery) * Neurological disorders affecting nausea (e.g. severe migraines and neuropathy) * Any known eating disorders (e.g. anorexia nervosa and bulimia) * Pregnancy or breastfeeding * Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) (\> 2 times normal values) or present hepatobiliary disease * Kidney disease (estimated glomerular filtration rate (eGFR)\<90 ml/min/1.73 m2) at screening * Severe arteriosclerotic heart disease or heart failure (NYHA class II-IV) * Glycated hemoglobin (HbA1c) ³ 48 mmol/mol and/or diagnosed type 1 or type 2 diabetes * Any condition that the investigator evaluates would interfere with study participation

Design outcomes

Primary

Measure	Time frame	Description
Change in GLP-1 induced nausea intensity	From enrollment to the end of treatment at up to 12 weeks.	The primary endpoint is the change in GLP-1-induced nausea intensity, measured by a 0-100 mm visual analogue scale (VAS), between study visits, with and without GIP infusion.

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 8, 2026